Mesenchymal stem cells for the treatment of systemic lupus erythematosus: is the cure for connective tissue diseases within connective tissue?

Flavio A. Carrion*, Fernando E. Figueroa

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

31 Citas (Scopus)

Resumen

Mesenchymal stem cells (MSCs) are now known to display not only adult stem cell multipotency but also robust anti-inflammatory and regenerative properties. After widespread in vitro and in vivo preclinical testing in several autoimmune disease models, allogenic MSCs have been successfully applied in patients with severe treatment-refractory systemic lupus erythematosus. The impressive results of these uncontrolled phase I and II trials - mostly in patients with non-responding renal disease - point to the need to perform controlled multicentric trials. In addition, they suggest that there is much to be learned from the basic and clinical science of MSCs in order to reap the full potential of these multifaceted progenitor cells in the treatment of autoimmune diseases.
Idioma originalInglés
Número de artículo23
PublicaciónStem Cell Research and Therapy
Volumen2
N.º3
DOI
EstadoPublicada - 2011

Nota bibliográfica

Publisher Copyright:© 2011 BioMed Central Ltd.

Palabras clave

  • Adult
  • Animals
  • Clinical Trials as Topic
  • Connective Tissue Diseases
  • Disease Models
  • Gene Expression Regulation
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Lupus erythematosus
  • Systemic
  • Lymphocyte Count
  • Lymphocyte Subsets
  • Mesenchymal Stem Cell Transplantation
  • Mice
  • Inbred NZB; Models
  • Biological
  • Transplantation
  • Heterologous
  • Homologous;
  • Treatment Outcome

Huella

Profundice en los temas de investigación de 'Mesenchymal stem cells for the treatment of systemic lupus erythematosus: is the cure for connective tissue diseases within connective tissue?'. En conjunto forman una huella única.

Citar esto